TY - JOUR
T1 - Preventing and treating biologic-associated opportunistic infections
AU - Winthrop, Kevin L.
AU - Chiller, Tom
N1 - Funding Information:
the findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Us centers for Disease control and prevention. K. L. Winthrop’s work on this manuscript was funded by an Agency for Healthcare research and Quality (AHrQ) grant (1K08Hs017552-01).
PY - 2009/7
Y1 - 2009/7
N2 - A variety of opportunistic pathogens have been reported to infect patients receiving tumor necrosis factor (TNF) antagonists for the treatment of autoimmune diseases. These pathogens are numerous, and include coccidioides, histoplasma, nontuberculous mycobacteria, Mycobacteria tuberculosis, and others of public health concern. Accordingly, TNF antagonists should be used with caution in patients at risk for tuberculosis, and screening for latent tuberculosis infection should be undertaken before anti-TNF therapy is initiated. Although screening and prevention efforts have decreased the risk of tuberculosis in this setting, optimal screening methods represent an area of evolving controversy. This article discusses the latest developments in screening methodologies for latent tuberculosis infection, as well as potential preventive and therapeutic considerations for opportunistic infections associated with anti-TNF agents and other biologic therapies.
AB - A variety of opportunistic pathogens have been reported to infect patients receiving tumor necrosis factor (TNF) antagonists for the treatment of autoimmune diseases. These pathogens are numerous, and include coccidioides, histoplasma, nontuberculous mycobacteria, Mycobacteria tuberculosis, and others of public health concern. Accordingly, TNF antagonists should be used with caution in patients at risk for tuberculosis, and screening for latent tuberculosis infection should be undertaken before anti-TNF therapy is initiated. Although screening and prevention efforts have decreased the risk of tuberculosis in this setting, optimal screening methods represent an area of evolving controversy. This article discusses the latest developments in screening methodologies for latent tuberculosis infection, as well as potential preventive and therapeutic considerations for opportunistic infections associated with anti-TNF agents and other biologic therapies.
UR - http://www.scopus.com/inward/record.url?scp=70349577776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349577776&partnerID=8YFLogxK
U2 - 10.1038/nrrheum.2009.105
DO - 10.1038/nrrheum.2009.105
M3 - Article
C2 - 19568254
AN - SCOPUS:70349577776
SN - 1759-4790
VL - 5
SP - 405
EP - 410
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
IS - 7
ER -